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Abstract
The insulin degrading enzyme (IDE) variant, v311 (rs6583817), is associated with increased post-mortem cerebellar IDE
mRNA, decreased plasma b-amyloid (Ab), decreased risk for Alzheimer’s disease (AD) and increased reporter gene
expression, suggesting that it is a functional variant driving increased IDE expression. To identify other functional IDE
variants, we have tested v685, rs11187061 (associated with decreased cerebellar IDE mRNA) and variants on H6, the
haplotype tagged by v311 (v10; rs4646958, v315; rs7895832, v687; rs17107734 and v154; rs4646957), for altered in vitro
reporter gene expression. The reporter gene expression levels associated with the second most common haplotype (H2)
successfully replicated the post-mortem findings in hepatocytoma (0.89 fold-change, p=0.04) but not neuroblastoma cells.
Successful in vitro replication was achieved for H6 in neuroblastoma cells when the sequence was cloned 59 to the promoter
(1.18 fold-change, p=0.006) and 39 to the reporter gene (1.29 fold change, p=0.003), an effect contributed to by four
variants (v10, v315, v154 and v311). Since IDE mediates Ab degradation, variants that regulate IDE expression could
represent good therapeutic targets for AD.
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Introduction
Aggregated b-amyloid (Ab) is a pathological hallmark of the
Alzheimer’s Disease (AD) brain. Mechanisms that alter the
production and clearance of toxic Ab in the brain therefore
represent good therapeutic targets for prevention and/or treat-
ment of AD. Insulin degrading enzyme (IDE), one of several Ab-
degrading proteases [1-4] identified to-date, has been shown to
mediate Ab degradation in vitro [5–7] via an IDE recognition motif
corresponding to residues 17–24; sites crucial for the formation of
Ab fibrils. Furthermore, Farris et al. reported that IDE knock-out
mice presented with a .50% decrease in Ab degradation in both
brain membrane fractions and primary neuronal cultures and
increased cerebral accumulation of endogenous Ab [8]. It follows
that disturbed IDE expression and/or activity could contribute to
amyloid fibril formation [9].
The gene encoding IDE (IDE), located on chromosome
10q23.33, represents a strong AD candidate gene because of its
location near a ‘‘suggestive’’ linkage peak (10q24) found in two
genome-wide linkage studies of late-onset AD (LOAD) families
[10,11] and a ‘‘significant’’ linkage peak (10q) in a third [12].
Several studies have reported significant association of IDE
haplotypes with LOAD [13,14,15], as well as with plasma Ab42
levels in extended LOAD families [14], with plaque density [13]
and cognitive function [14].
In our recent publication we identified three IDE haplotypes
(H2, H6 and H9) associated with altered IDE transcript levels in
post-mortem cerebellum [15]. A summary of the composition of
these haplotypes and our previous findings are shown in Table 1.
Since rs6583817 (v311), a variant present on both H6 and H9, was
individually associated with an increase in the level of IDE
transcript, increased in vitro reporter gene expression and
decreased risk of LOAD, we proposed a simple model in which
v311 is the functional variant that influences IDE expression and
LOAD risk. This was supported by the finding that rs5786996
(v3), a variant tagging H9, although associated with increased IDE
transcript and decreased risk for LOAD, showed a conflicting
decreased in vitro reporter gene expression and was thus unlikely to
be the functional variant driving increased transcript levels.
However, the observation that the ,1.4-fold increase in vitro
previously we reported for v311 did not compare to the 2.1-fold
increase we observed in post-mortem cerebellum samples could
indicate that rather than a single variant model for functionality, a
combination of relatively small effects on gene expression resulting
from multiple variants may produce larger and significant changes
in gene expression.
In order to thoroughly investigate other potentially functional
IDE variants we have tested five variants for altered in vitro reporter
gene expression, based on their presence on haplotypes (H2, H6
and H9) and their association with altered IDE mRNA transcript
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rs11187061 (v685), present on H2, a haplotype associated with
significantly decreased cerebellar IDE mRNA levels. Secondly,
three variants (rs4646958; v10, rs7895832; v315 and rs17107734;
v687) that are in near complete linkage disequilibrium (LD; all
pair-wise D’,98, r
2.90) and arise on one (H6) of the two
haplotypes tagged by v311. Due to this strong LD, all three
variants and v311 have near identical significant association (2.07–
2.20 fold increase) with cerebellar IDE mRNA levels and all lie in
conserved intronic regions of IDE. Finally, we also tested
rs4646957 (v154), the most frequent of these IDE variants, which
is present on five IDE haplotypes, two of which (H6 and H9)
showed significantly increased cerebellar IDE mRNA levels.
Methods
Cloning
Approval was obtained from the ethics committee and
institutional review board for the ascertainment and collection of
samples (Mayo Clinic College of Medicine, Jacksonville). Written
informed consent was obtained for all individuals that participated
in this study. DNA sequence fragments surrounding each variant
were each cloned into a pGL3P vector (Promega) containing the
Firefly Luciferase gene and an SV40 promoter using the Gateway
cloning system (Invitrogen). AttB-flanked primers (Table 2) specific
to the region surrounding the fragments were used to amplify
genomic DNA extracted from individuals known to be homozy-
gous for the major or minor allele of each variant. PCR reactions
were performed in a reaction mix containing 1xPCR buffer
containing 1.5mM MgCl2 (QIAGEN), 1 mM dNTPs (Promega),
0.2 mM each primer, 2.5U HotStar Taq DNA polymerase and
20 ng genomic DNA to a final volume of 25 ml. Amplification
conditions were as follows; 95uC for 5 minutes, followed by 35
cycles of 95uC for 30 seconds, annealing temperature (Table 2) for
1 minute, 72uC for 1 minute and finally an extension step of 72uC
for 10 minutes. The resultant amplicons (major and minor allele)
were extracted from an ethidium bromide-stained agarose gel
using a QIAquick Spin kit (QIAGEN) and verified by sequencing
(Mayo Clinic, Rochester) to ensure no other variants were present
in the clone. Since v685 and v687 are only 8 bp apart, it was
unavoidable that both variants would be present in the same
amplicon. As a result, sequencing was used to ensure that both
v685 major and minor allele test amplicons contained the major
allele at v687 and both v687 amplicons contained the major allele
at v685. The attB-flanked fragments were integrated via bacterial
recombination into a kanamycin-resistant pDONR 221 vector
using the BP Clonase II system (Invitrogen) to produce an entry
clone. Entry clones were transformed into Library efficiency
DH5a chemically competent E.coli (Invitrogen) and grown on
Luria broth (LB) agar containing 50 mg/ml kanamycin overnight
at 37uC. Single colonies were picked for inoculation in liquid LB
broth containing 50 mg/ml kanamycin and incubated overnight in
a shaking incubator at 37uC. Plasmids were extracted from the
bacterial cells using a QIAprep spin kit (QIAGEN). Final
expression clones were constructed by recombination of the entry
clones with ampicillin resistant pGL3 promoter vector using the
Table 1. Summary of 17 IDE variants and haplotype composition.
Single variant
information
Haplotype
composition
Variant mRNA
association
vID rs Maj Min Position Location Cons. MAF H2 H6 H9 D p
2 - AA -- 94202383 39 81% 2% 0 0 0
3 rs5786996 - C 94202516 39 74% 4% 0 0 1 2.12 0.0005
6 rs5786997 -- AT 94203071 39 88% 10% 0 0 0
10 rs4646958 A T 94204339 Int24 75% 9% 0 1 0 2.2 4.2610
26
154 rs4646957 G A 94219892 Int18 71% 36% 0 1 1 1.22 0.02
309 - G T 94236972 Ex13 92% 2% 0 0 0
310 - T C 94237153 Int12 72% 2% 0 0 0
311 rs6583817 G A 94237227 Int12 74% 13% 0 1 1 2.12 1.5610
28
176 rs17875327 T C 94264789 Int4 85% 10% 0 0 0
315 rs7895832 T A 94266506 Int4 83% 9% 0 1 0 2.19 6.3610
26
46 rs4646955 T C 94284271 Int3 76% 25% 0 0 0
684 rs17107721 G A 94288480 Int1 71% 5% 0 0 0
180 rs11187060 G A 94294112 Int1 70% 33% 0 1 1 1.22 0.02
683 rs17445328 A G 94295169 Int1 72% 25% 0 0 0
685 rs11187061 C T 94295389 Int1 70% 19% 1 0 0 0.78 0.009
687 rs17107734 C T 94295397 Int1 70% 9% 0 1 0 2.07 1.8610
25
776 rs11187074 C G 94316926 Int1 73% 19% 1 0 0 0.80 0.02
Haplotype Frequency 18% 8% 3%
Haplotype mRNA association D 0.79 2.24 2.34
p 0.03 1610
25 0.006
The variant ID (vID), rs number (where available), major (Maj) and minor (Min) allele, Chromosomal position, location within the gene, % conservation of surrounding
sequence with mouse and rat genomes and minor allele frequency (MAF) are detailed for each variant. The allele composition of the three haplotypes studied here are
defined as 0=major allele, 1=minor allele. The fold-difference (D) in cerebellar IDE mRNA levels are given for each individual variant and haplotype that demonstrated
significance at the p,0.05 level only.
doi:10.1371/journal.pone.0021429.t001
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transformed into DH5a E.Coli and grown on LB agar containing
100 mg/ml ampicillin and single colonies were inoculated in LB
broth containing 100 mg/ml ampicillin. Plasmids were extracted
using endotoxin-free Zyppy Plasmid miniprep kit (Zymo research)
and verified by sequencing. Four expression clones per variant
were made in total; (1) major and (2) minor allele sequence cloned
50 to the SV40 promoter and Firefly Luciferase, and (3) major and (4)
minor allele sequence cloned 30 to Firefly Luciferase gene.
Cell Culture
Human neuroblastoma (Be(2)-C) and hepatocellular carcinoma
(HepG2) immortalized cell lines were supplied by ATCC. Cells
were cultured in Eagle Minimum Essential Medium (EMEM)
supplemented with 10% fetal bovine serum, 2 mM L-Glutamine,
1X non-essential amino acids, 1000 U/ml Penicillin-Streptomycin
(Sigma), 2.5 mg/ml Fungizone (Invitrogen). All cultures were
incubated at 37uC in 5% CO2.
Transfection
16105 Be(2)-C cells or 36105 HepG2 cells were plated in 12-
well culture plates 24 hours before transfection. Cells were co-
transfected in triplicate with the IDE expression clones and a pRL
vector (Promega) containing the Renilla Luciferase reporter gene.
Control wells included cotransfection of either pGL3 B (empty
pGL3vector) or P (containing the SV40 promoter) with pRL. On
day of transfection, cells were washed twice with PBS and media
was replaced with 400 ml serum-free EMEM containing 200 ng
expression clone or control vector, 10 ng pRL and transfection
reagent Tfx-20 (Promega) at a charge ratio of 3:1 (Tfx:DNA) per
well. Transfection mix was pre-incubated for 15 minutes at room
temperature. One hour after transfection, 800 ml complete
EMEM was added to each well.
Dual Luciferase Reporter Assay
Cells were washed twice with PBS and harvested with 200 mlo f
1x Lysis buffer (Promega) for 20 minutes on a rocking platform
48 hours after transfection. The resultant lysates (5 ml) were plated
in a white 96-well assay plate. Firefly Luciferase and Renilla
Luciferase signals were measured by a Veritas microplate
luminometer (Turner Biosystems) using the Dual Luciferase
Reporter Assay System (Promega).
Statistical Analyses
The ratio of Firefly Luciferase to Renilla Luciferase activity
(Relative Luciferase Activity; RLA) was used to normalize
Luciferase activity for intra-experimental transfection efficiency.
Unpaired t-tests were used to compare mean RLA for all
expression clones. Relative RLA (RRLA) to pGL3P was expressed
as RLA for each IDE sequence as a percentage of RLA for
pGL3P. The mean RRLA values for the major or minor allele that
comprise each haplotype were used to generate a ‘‘Haplotype
RRLA’’. ‘‘Haplotype RRLA’’ for each haplotype were compared
to H1 using paired t-tests. All statistics were performed using
StatsDirect 2.6.1. Promoter sequences for IDE were identified
using the ElDorado function of the Genomatix database (www.
genomatix.de). Putative transcription factor binding sites were
searched for in silico using the MatInspector tool of the Genomatix
database; the DNA sequence of the regions surrounding the major
and minor allele of each variant were compared for the presence
of binding sites of known human transcription factors.
Results
Each IDE sequence (surrounding either the major or minor
allele of each variant) was cloned in two locations of the pGL3P
vector; 59 to the SV40 promoter and 39 to Firefly Luciferase in order
to see if the putative function of the variant would be specific to its
position relative to the gene. As shown in Table 1, all the variants
tested here are either intronic or lie in the 39 flanking region. Since
none of these variants lie within 1.5 kb of a promoter region (as
defined by the ElDorado function at genomatix, www.genomatix.
de), all variants were tested for enhancer rather than promoter
activity. Classically, you might expect intronic enhancer or
flanking sequences to work in both orientations (59 or 39 to the
reporter gene) and that a genuine functional effect would be seen
independent of where it was cloned. We transfected these vectors
into a neuroblastoma cell line (Be(2)-C), and in order to assess
tissue specificity, we also transfected the same vectors into a
hepatocellular carcinoma cell line (HepG2).
As shown in Figure 1a, contrasting association was observed for
v685 major allele sequence compared to minor allele sequence in
Be(2)-C and HepG2 cells. In Be(2)-C cells, although v685 minor
allele sequence showed a non significant 0.82-fold RLA when
cloned 59 to the promoter (p=0.82), a significantly 1.65-fold RLA
was observed when cloned 39 to the reporter gene (p=0.009). In
the HepG2 cells, a significant decrease in RLA was associated
with the minor allele in both locations (59=0.89-fold, p=0.003;
39=0.87-fold, p=0.007), thus providing consistent association
independent of cloning location and demonstrating a better
correlation with decreased cerebellar IDE mRNA levels than
Be(2)-C cells. An in silico search for putative transcription factor
binding sites created or destroyed by the v685 minor allele (T)
Table 2. IDE variant specific primer sequences.
vID rs number Sense primer (59 to 39) Antisense primer (59 to 39) Size Major Minor AT (6C)
685 rs11187061 GCAAGCAACAAGGATTGGAT CCAAATTGCATGTCTGTAGCA 371 C T 64
10 rs4646958 GCCTCAAGCCAAAACAAAAA TCACTTCAGGCTGCAAAGAA 143 A T 62
315 rs7895832 GCTGGAGAGTTATAAAAATAGCATTG TTGTGGAAAGAAATTTACTATTTTGG 118 T A 63
687 rs17107734 GCAAGCAACAAGGATTGGAT CCAAATTGCATGTCTGTAGCA 371 C T 64
154 rs4646957 GAGGCAGCCATGAAAGTTAGG GGTGGTTGAGGTTTTAGCAATC 204 C T 61
Primers specific for sequences in IDE surrounding each variant were used to generate attB- tagged products for cloning; sequences were amplified from DNA taken from
individuals known to be homozygous for the major and minor allele indicated in the ‘‘Major’’ and ‘‘Minor’’ columns; vID; variant identification number, rs number; dbSNP
variant identifier, Size; PCR product size (base pairs), AT; annealing temperature used for the amplification of each sequence.
doi:10.1371/journal.pone.0021429.t002
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factor in the liver or brain is unknown, therefore we are unable to
assess whether this may exert the tissue-specific effects we observed
for this variant.
Figure 1b shows that v10 minor allele sequence was associated
with 1.36-fold RLA compared to v10 major allele sequence albeit
only when positioned 59 to the promoter and only in Be(2)-C
neuroblastoma cells (p=0.02). Although a similar 1.31-fold RLA
was observed for v10 in HepG2 hepatocellular cells at the 59
location, the association was not significant (p=0.22). Notably, we
found that the v10 minor allele (T) destroys a putative binding site
for MYT1, a repressor with brain and central nervous system
specificity, which could explain the tissue-specific enhanced
expression that we observed for this variant.
As shown in Figure 1c, in Be(2)-C cells, v315 minor allele se-
quence was also significantly associated with 1.71-fold RLA when
comparedtov315major allelesequencealbeit whenpositioned39 to
the Firefly Luciferase reporter gene only (p=0.02). A non-significant
1.42-fold RLA was observed in HepG2 cells in the 39 location
(p=0.16). A search for putative transcription factor binding site at
this locus revealed the destruction of an HMBOX1 site and the
creation of TBP and VDR sites associated with the minor allele (A).
HMBOX1 and VDR both function in the liver but have no known
effects in the brain. The tissue-specificity of TBP is unknown. Since,
significant association of v10 or v315 with in vitro reporter gene
expression was inconsistent between cloning locations or between
cell lines, we provide little evidence that v10 or v315 individually
drive altered gene expression using this in vitro system. Figures 1d-e
show that neither v687 nor v154 minor allele sequence were
significantly associated with altered RLA in either location in either
cell line when compared to major allele sequence (all p.0.07).
These data provide an indication of how IDE variants exert
effects on gene expression in vitro at the individual variant level.
However, in addition to the individual variant effects, our previous
publication reported altered IDE mRNA expression in post-
mortem cerebellum between haplotypes. These haplotype-specific
expression levels may be caused by an individual haplotype-
tagging variant that is capable of altering gene expression levels to
an extent that it can either drive the overall expression levels or
can overcome any opposing effects of other variants present on the
haplotype. Alternatively, a combination of many functional
variants may act collectively to result in an overall increase or
decrease in gene expression and will therefore only be detected by
collecting data from multiple variants on the same haplotype. In
an attempt to better understand how these variants may affect
gene expression at the haplotypic level we first calculated the
relative RLA (RRLA) to pGL3P. Since pGL3P contains the SV40
promoter but no IDE sequence, the RRLA provides a measure of
whether the IDE sequence exerts enhanced or repressed RLA.
RRLA was calculated for each major and minor allele sequence
Figure 1. Functional effects of sequences surrounding five IDE variants on in vitro reporter gene expression. Relative Luciferase Activity
(RLA; relative Firefly:Renilla Luciferase values) is shown for A) v685, B) v10, C) v315, D) v687 and E) v154 in Be(2)-C and HepG2 cell lines. Constructs
containing sequence surrounding major allele are shown as white bars and those containing sequence surrounding minor allele are shown as shaded
bars. IDE sequences were cloned either 59 to the promoter or 39 to Firefly Luciferase. Error bars represent standard error of the mean. * p=0.0520.01,
** p=0.00920.0001.
doi:10.1371/journal.pone.0021429.g001
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in our previous publication. The combined RRLA values for
variants comprising H2 (minor allele at v685), H6 (minor allele at
v10, v315, v687, v154 and v311) and H9 (minor allele at v154,
v311 and v3) were then compared to the most common haplotype,
H1 (major allele of each variant). The RRLA values and the
composition of each haplotype (0=major allele, 1=minor allele) are
tabulated in Figure 2. The RRLA values for sequences comprising
H2, H6 and H9 were then plotted as fold-change in RRLA for the
equivalent sequence in H1 (Figure 2).
As shown in Figure 2c, when cloned 39to Firefly Luciferase and
transfected into Be(2)-C cells the v685 minor allele sequence
comprising H2 (66.1%) was associated with 1.65-fold RRLA
relative to the v685 major allele sequence that comprises H1
(40.0%). v685 is the only one of the seven variants we tested that
differs between H2 and H1, despite this, the overall RRLA for
sequence comprising H2 was associated with 1.06-fold RRLA
relative to H1 (69.2% vs 65.5%; p=0.05). In contrast, in HepG2
cells (Figure 2d) the v685 minor allele was associated with near
identical decreases in RRLA for the 59 and 39 constructs (0.89 and
Figure 2. Relative RLA of IDE putative functional variants and haplotypes. Relative RLA levels to pGL3P (RRLA), expressed as % pGL3P
expression are tabulated for each variant comprising a–b) H1, c–d) H2, e–f) H6, g–h) H9. 0=major allele, 1=minor allele. H1=the most common IDE
haplotype comprising the major allele at each variant. The RRLA for each sequence comprising haplotypes H2, H6 and H9 are plotted relative to the
sequence comprising H1, expressed as fold-change in RRLA relative to H1. ‘‘Haplotype RRLA’’ is the averaged % RRLA for the variants in each
haplotype. All standard error of the mean RRLA ,0.7. P-values resulting from paired t-tests comparing ‘‘Haplotype RRLA’’ values for H2, H6 or H9 vs
H1 are also shown.
doi:10.1371/journal.pone.0021429.g002
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comprising H1. The altered expression at v685 alone was
sufficient to provide a significant association with 0.99-fold RRLA
for H2 sequences compared to H1 sequences at the 59 location
(141.6% vs 142.8%; p=0.04). The data from HepG2 cells
therefore correlated better with the decreased cerebellar IDE
transcript levels than Be(2)-C cells.
In Be(2)-C cells, the sequences comprising the H6 haplotype
were all associated with either equal or enhanced RRLA when
compared to the sequences comprising H1 (Figure 2e). When
cloned 59 to the SV40 promoter, the minor allele sequences
associated with the greatest fold change in RRLA relative to
major allele sequences comprising H1 were v10 (1.36-fold), v154
(1.46-fold) and v311 (1.35-fold), whereas when cloned 39 to the
SV40 promoter, it was v315 (1.71-fold), v154 (1.50-fold) and v311
(1.36-fold). Overall, the altered expression associated with the
sequences comprising H6 at both 59 and 39 location was
significantly increased (1.18-fold and 1.29-fold, respectively)
compared to the sequences comprising H1 (111.0% vs 94.2%;
p=0.006 and 84.5% vs 65.5%; p=0.003, respectively). In HepG2
cells, a similar association was observed (Figure 2f); v10 (1.31-fold),
v154 (1.24-fold) and v311 (1.31-fold) minor allele sequences drove
an overall significant 1.11-fold RRLA associated with H6
compared to sequences comprising H1 although only at the 50
location (158.5% vs 142.8%; p=0.05). These data provide support
for the hypothesis that multiple variants (v10, v154, v315 and
v311) may contribute to the increased IDE transcript levels
observed from post-mortem cerebellum samples.
In accordance with the fact that v154 and v311 comprise both
H6 and H9, the same result was observed for these two variants in
H9 (Figure 2g-h). In addition to v154 and v311, H9 comprises the
v3 minor allele sequence associated with 0.77-fold and 0.29-fold
RRLA when cloned in the 59 and 39 locations respectively in
Be(2)-C cells and 0.67-fold and 0.26-fold RRLA in HepG2 cells.
Although v154 and v311 consistently showed an increase in
RRLA, the effect observed with the minor allele of v3 led to an
overall RRLA associated with sequence comprising H9 that was
not significantly altered compared to RRLA associated with
sequence comprising H1. These data suggest that v154 and v311
may be the variants driving the increased gene expression we
observed for H6 in post-mortem cerebellum samples.
Discussion
Here we have tested five IDE variants for altered reporter gene
expression and evaluated their contribution to the altered
cerebellar IDE mRNA associations reported for the haplotypes
they comprise. We have attempted to address the complex issue of
how individual variants within a haplotypic backbone contribute
to the ‘‘global’’ functional effect of that haplotype rather than
solely concentrating on each variant as a singleton.
Firstly, the minor allele at v685, was significantly associated with
0.89-fold and 0.87-fold RLA when cloned 59 to the promoter and
39 to Firefly Luciferase in HepG2 cells, respectively.
However, these associations were not replicated in Be(2)-C cells,
more than likely indicating tissue-specific differences in function-
ality. Likewise, when we compared the RRLA for the sequences
comprising H2 for all seven IDE variants for which we have
dual Luciferase Assay data with the RRLA for the sequences
comprising the most common haplotype (H1), we found the same
conflicting results between Be(2)-C and HepG2. Based on the
assumption that Be(2)-C neuroblastoma cells correlate better with
the cells taken from the cerebellum samples than the HepG2
hepatocytoma cells, these findings provide little evidence that v685
is the functional variant contributing to the significant decrease in
IDE mRNA levels.
Five of the variants studied (v10, v315, v687, v154, v311) are
present on the sixth most common IDE haplotype, H6. Due to the
lack of consistency in association between cell lines and cloning
locations for all except v311, we have little evidence that these
variants can individually drive altered gene expression. Instead we
show that when comparing the RRLA for the sequences
comprising H6 vs H1, variants v10, v315, v154 and v311 (but
not v687) contributed towards increased RLA associated with H6.
Along with v3, the variants, v154 and v311 occur on H9, a
haplotype significantly (p=0.006) associated with 2.34-fold IDE
mRNA in post-mortem cerebellum samples. We found no
significant difference in RRLA between H9 sequences and H1
sequences. This suggests that if there is a true association of H9
with IDE mRNA levels, it may be contributed to by variants other
than v311 and v154, which were not sufficient to significantly
increase the RRLA.
There are some provisos to the reporting of a lack of
functionality associated with variants using the in vitro system
incorporated here. (1) Due to LD within the region, the variants
tested may tag the truly functional IDE variant; e.g. v776 is in
perfect LD with v685 (D’and r
2=1.0). In addition, one other
variant in H2 (rs11187059) was not investigated in our association
studies due to strong LD with v685 (r2=0.97). We are unaware of
any other variant lying in a conserved region of IDE that is present
on this haplotype. Regarding H6 and H9, only one variant in
conserved regions remains untested (v180) due to its presence on
multiple haplotypes. (2) Haplotypes may appear functional in
opposing directions to another haplotype (eg. H2 vs H6) merely
because they possess the opposing allele of a truly functional
variant. (3) The in vitro model may not accurately reflect the
complexity of in vivo IDE regulation. A larger sample size may be
required to gain substantial power to detect mild effects on gene
expression.
Experimental error may also confound attempts to observe
these effects; we calculated the coefficient of variation (%CV;
standard deviation RLA/mean RLA*100) as a statistic for
comparing the degree of variation in RLA across triplicates. In
the 210 transfections performed, the %CV was ,25% in 93.3% of
the transfections and always ,40%. Although a %CV ,25%
indicates relatively little variation for an in vitro study, it may be
sufficient to reduce the power to detect subtle effects on RLA.
Furthermore, it is well recognized that cis-regulatory function is
context dependent [16]. These experiments were conducted under
basal conditions and would therefore not detect altered gene
expression as a result of stimulation by inflammation or oxidative
stress that may occur in the AD brain. In addition, a regulatory
variant may require interaction with intronic sequence or other
downstream regulatory elements to exert its function [16], thus
highlighting a limitation of the Dual Luciferase Assay, which
allows only small areas of the genome to be tested at once. (4)
Variants may exert effects via a mechanism other than altered
transcription factor binding, e.g. by affecting mRNA processing,
pre-mRNA splicing, mRNA stability, mRNA trafficking, or
regulatory RNAs. (5) The association of variants with altered
IDE mRNA previously observed may have been a false positive
finding; it must be noted that the p-value for association of v685
with altered IDE transcript (p=0.009) just missed the Bonferroni
corrected significance level (p=0.005) for the ten variants tested.
We currently do not have sufficient evidence to distinguish
between these possibilities.
In summary, we have identified multiple, functional variants
residing in conserved, non-coding IDE sequence that alter reporter
IDE Variants Alter Reporter Gene Expression
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with IDE mRNA transcript in post-mortem cerebellum samples.
Since IDE has been shown to mediate Ab degradation in vitro
[5-7], variants that regulate IDE expression could represent good
therapeutic targets for LOAD.
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